Quenching-induced deactivation of photosensitizer by nanoencapsulation to improve phototherapy of cancer

References

• Agostinis P, Vantieghem A, Merlevede W, De Witte PAM. (2002). Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol, 34, 221–241.
   PubMed Web of Science ®Google Scholar
• Allison RR, Mota HC, Bagnato VS, Sibata CH. (2008). Bio-nanotechnology and photodynamic therapy―State of the art review. Photodiagn Photodyn Ther, 5, 19–28.
   PubMed Web of Science ®Google Scholar
• Aveline BM, Hasan T, Redmond RW. (1995). The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). J Photochem Photobiol B, 30, 161–169.
   Google Scholar
• Campo MA, Gabriel D, Kucera P, Gurny R, Lange N. (2007). Polymeric photosensitizer prodrugs for photodynamic therapy. Photochem Photobiol, 83, 958–965.
   PubMed Web of Science ®Google Scholar
• Chen J, Stefflova K, Niedre MJ, Wilson BC, Chance B, Glickson JD, Zheng G. (2004). Protease-triggered photosensitizing beacon based on singlet oxygen quenching and activation. J Am Chem Soc, 126, 11450–11451.
   PubMed Web of Science ®Google Scholar
• Clo E, Snyder JW, Ogilby PR, Gothelf KV. (2007). Control and selectivity of photosensitized singlet oxygen production: challenges in complex biological systems. Chembiochem, 8, 475–481.
   PubMed Web of Science ®Google Scholar
• Clo E, Snyder JW, Voigt NV, Ogilby PR, Gothelf KV. (2006). DNA-programmed control of photosensitized singlet oxygen production. J Am Chem Soc, 128, 4200–4201.
   PubMed Web of Science ®Google Scholar
• D’Hallewin MA, Bezdetnaya L, Guillemin F. (2002). Fluorescence detection of bladder cancer: a review. Eur Urol, 42, 417–425.
   PubMed Web of Science ®Google Scholar
• Davda J, Labhasetwar V. (2002). Characterization of nanoparticle uptake by endothelial cells. Int J Pharm, 233, 51–59.
   PubMed Web of Science ®Google Scholar
• Derycke AS, de Witte PA. (2004). Liposomes for photodynamic therapy. Adv Drug Deliv Rev, 56, 17–30.
   PubMed Web of Science ®Google Scholar
• Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. (1997). The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res, 14, 1568–1573.
   PubMed Web of Science ®Google Scholar
• Dolmans DEJG, Fukumura D, Jain RK. (2003). Photodynamic therapy for cancer. Nat Rev Cancer, 3, 380–387.
   PubMed Web of Science ®Google Scholar
• Etzlstorfer C, Falk H. (2000). Concerning the association of hypericin tautomers and their hypericinate ions. Monatshefte für Chemie, 131, 333–340.
   Web of Science ®Google Scholar
• Falk H, Meyer J. (1994). On the homo- and heteroassociation of hypericin. Monatshefte für Chemie, 125, 753–762.
   Web of Science ®Google Scholar
• Gabriel D, Campo MA, Gurny R, Lange N. (2007). Tailoring protease-sensitive photodynamic agents to specific disease-associated enzymes. Bioconjug Chem, 18, 1070–1077.
   PubMed Web of Science ®Google Scholar
• Gaumet M, Gurny R, Delie F. (2009). Localization and quantification of biodegradable particles in an intestinal cell model: The influence of particle size. Eur J Pharm Sci, 36, 465–473.
   PubMed Web of Science ®Google Scholar
• Hamblin MR, Miller JL, Rizvi I, Loew HG, Hasan T. (2003). Pegylation of charged polymer-photosensitiser conjugates: effects on photodynamic efficacy. Br J Cancer, 89, 937–943.
   PubMed Web of Science ®Google Scholar
• Hamblin MR, Miller JL, Rizvi I, Ortel B, Maytin EV, Hasan T. (2001). Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res, 61, 7155–7162.
   PubMed Web of Science ®Google Scholar
• Hopper C. (2000). Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol, 1, 212–219.
   PubMedGoogle Scholar
• Huygens A, Kamuhabwa AR, de Witte PA. (2005). Stability of different formulations and ion pairs of hypericin. Eur J Pharm Biopharm, 59, 461–468.
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, Maeda H. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today, 11, 812–818.
   PubMed Web of Science ®Google Scholar
• Jocham D, Stepp H, Waidelich R. (2007). Photodynamic diagnosis in urology: state-of-the-art. Eur Urol, 53, 1138–1150.
   PubMed Web of Science ®Google Scholar
• Kamuhabwa A, Agostinis P, Ahmed B, Landuyt W, Van Cleynenbreugel B, Van Poppel H, De Witte P. (2004). Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder. Photochem Photobiol Sci, 3, 772–780.
   PubMed Web of Science ®Google Scholar
• Komagoe K, Tamagake K, Katsu T. (2006). The influence of aggregation of porphyrins on the efficiency of photogeneration of hydrogen peroxide in aqueous solution. Chem Pharm Bull (Tokyo), 54, 1004–1009.
   PubMed Web of Science ®Google Scholar
• Konan YN, Berton M, Gurny R, Allemann E. (2003a). Enhanced photodynamic activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur J Pharm Sci, 18, 241–249.
   PubMed Web of Science ®Google Scholar
• Konan YN, Cerny R, Favet J, Berton M, Gurny R, Allemann E. (2003b). Preparation and characterization of sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy. Eur J Pharm Biopharm, 55, 115–124.
   PubMed Web of Science ®Google Scholar
• Konan YN, Gurny R, Allemann E. (2002). State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B, 66, 89–106.
   PubMed Web of Science ®Google Scholar
• Konan-Kouakou YN, Boch R, Gurny R, Allemann E. (2005). In vitro and in vivo activities of verteporfin-loaded nanoparticles. J Control Release, 103, 83–91.
   PubMed Web of Science ®Google Scholar
• Lavie G, Mazur Y, Lavie D, Meruelo D. (1995). The chemical and biological properties of hypericin - A Compound with a broad-spectrum of biological activities. Med Res Rev, 15, 111–119.
   PubMed Web of Science ®Google Scholar
• McCarthy JR, Perez JM, Bruckner C, Weissleder R. (2005). Polymeric nanoparticle preparation that eradicates tumors. Nano Lett, 5, 2552–2556.
   PubMed Web of Science ®Google Scholar
• Mosinger J, Mosinger B. (1995). Photodynamic sensitizers assay: rapid and sensitive iodometric measurement. Experientia, 51, 106–109.
   PubMedGoogle Scholar
• Oba T. (2007). Photosensitizer nanoparticles for photodynamic therapy. Curr Bioact Compd, 3, 239–251.
   Google Scholar
• Qaddoumi MG, Ueda H, Yang J, Davda J, Labhasetwar V, Lee VH. (2004). The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res, 21, 641–648.
   PubMed Web of Science ®Google Scholar
• Rijcken CJ, Hofman JW, van Zeeland F, Hennink WE, van Nostrum CF. (2007). Photosensitiser-loaded biodegradable polymeric micelles: preparation, characterisation and in vitro PDT efficacy. J Control Release, 124, 144–153.
   PubMed Web of Science ®Google Scholar
• Saw CL, Olivo M, Soo KC, Heng PW. (2005). Delivery of hypericin for photodynamic applications. Cancer Lett, 241, 23–30.
   PubMed Web of Science ®Google Scholar
• Schneider R, Tirand L, Frochot C, Vanderesse R, Thomas N, Gravier J, Guillemin F, Barberi-Heyob M. (2006). Recent improvements in the use of synthetic peptides for a selective photodynamic therapy. Anticancer Agents Med Chem, 6, 469–488.
   PubMedGoogle Scholar
• Sharman WM, Allen CM, van Lier JE. (1999). Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today, 4, 507–517.
   PubMed Web of Science ®Google Scholar
• Sharman WM, van Lier JE, Allen CM. (2004). Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev, 56, 53–76.
   PubMed Web of Science ®Google Scholar
• Smith RP. (2002). Photodynamic therapy. Curr Probl Cancer, 26, 67–108.
   PubMed Web of Science ®Google Scholar
• Solban N, Rizvi I, Hasan T. (2006). Targeted photodynamic therapy. Lasers Surg Med, 38, 522–531.
   PubMed Web of Science ®Google Scholar
• Tanielian C, Schweitzer C, Mechin R, Wolff C. (2001). Quantum yield of singlet oxygen production by monomeric and aggregated forms of hematoporphyrin derivative. Free Radic Biol Med, 30, 208–212.
   PubMed Web of Science ®Google Scholar
• Theodossiou T, Spiro MD, Jacobson J, Hothersall JS, Macrobert AJ. (2004). Evidence for intracellular aggregation of hypericin and the impact on its photocytotoxicity in PAM 212 murine keratinocytes. Photochem Photobiol, 80, 438–443.
   PubMed Web of Science ®Google Scholar
• Triesscheijn M, Baas P, Schellens JHM, Stewart FA. (2006). Photodynamic therapy in oncology. Oncologist, 11, 1034–1044.
   PubMed Web of Science ®Google Scholar
• Van de Putte M, Roskams T, Bormans G, Verbruggen A, de Witte PA. (2006). The impact of aggregation on the biodistribution of hypericin. Int J Oncol, 28, 655–660.
   PubMed Web of Science ®Google Scholar
• van Dongen GA, Visser GW, Vrouenraets MB. (2004). Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev, 56, 31–52.
   PubMed Web of Science ®Google Scholar
• van Nostrum CF. (2004). Polymeric micelles to deliver photosensitizers for photodynamic therapy. Adv Drug Deliv Rev, 56, 9–16.
   PubMed Web of Science ®Google Scholar
• Verma S, Watt GM, Mai Z, Hasan T. (2007). Strategies for enhanced photodynamic therapy effects. Photochem Photobiol, 83, 996–1005.
   PubMed Web of Science ®Google Scholar
• Wynn JL, Cotton TM. (1995). Spectroscopic properties of hypericin in solution and at surfaces. J Phys Chem, 99, 4317–4323.
   Web of Science ®Google Scholar
• Zeisser-Labouèbe M, Lange N, Gurny R, Delie F. (2006a). Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int J Pharm, 326, 174–181.
   PubMed Web of Science ®Google Scholar
• Zeisser-Labouèbe M, Vargas A, Delie F. (2006b). Nanoparticles for photodynamic therapy of cancer. In: Kumar CS (ed.), Nanomaterials for Cancer Therapy (Vol. 6, pp. 40–86 ). Weinheim: Wiley-VCH.
   Google Scholar
• Zheng G, Chen J, Stefflova K, Jarvi M, Li H, Wilson BC. (2007). Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proc Natl Acad Sci USA, 104, 8989–8994.
   PubMed Web of Science ®Google Scholar